Hoffmann–La Roche
Genentech Drops The Other Shoe
We all knew it was just a matter of time until the “special committee” appointed to review the Roche officially rejected the buyout offer of $89/share.
The press release indicates a willingness to listen to offers that “recognizes the value of the company and reflects the significant benefits that would accrue” to an acquiring company.
Move along [...]
Roche on Spending Spree
First Roche offers to buy Genentech for ~$44B and in two consecutive days has inked two more deals.
Yesterday, in its second RNAi play in a year, Roche bought Mirus Bio for $125M. The acquisition should add value to the July 2007 preclinical discovery deal with RNAi leader Alnylam. Under the agreement, Mirus will [...]
Will Roche Kill Independent Genentech?
Roche has offered to buy the 45% stake of Genentech it doesn’t already own with a $89/share, $43.7B (8.8% premium) offer.
The initial Roche/Genentech deal brokered in the 90’s has been key to Roche’s success in the last few years. Upon first blush, this deal seems a natural fit and a no-brainer for Roche but [...]
Recent Comments